In humans with acute myocardial infarction who had successful reperfusion with primary or rescue percutaneous coronary intervention (PCI), clinical trials with intravenous administration of EPO analogues did not show to reduce infarct size nor did it improve left ventricular ejection fraction. This evidence concerns the gene EPO and myocardial infarction.